| Outcome Measures: |
Primary: Evaluation of Area Under the Curve From Time 0 to Infinity, Area under the plasma concentration versus time curve from time 0 to infinity for daptomycin doses, Within 30 minutes prior to the start of the infusion, mid-infusion, and end of the infusion; at 1, 2, 4, 6, 9, 24, and 48 hours after the end of the infusion; and just prior to the next hemodialysis session (i.e., 68 hours post-infusion) | Secondary: Treatment-emergent Adverse Events, Safety was monitored throughout the study, including observation and reports of AEs as well as changes in physical findings, vital signs, ECGs, and laboratory tests., Up to 9 days after the last dose of study drug administration (Day 13 to Day 17 for those dosed on Day 8 and Day 20 to Day 24 for those dosed on Day 15). | Other: Maximum Plasma Concentration, Maximum plasma concentration over the entire sampling phase directly obtained from the experimental plasma concentration time data, without interpolation., Within 30 minutes prior to the start of the infusion, mid-infusion, and end of the infusion; at 1, 2, 4, 6, 9, 24, and 48 hours after the end of the infusion; and just prior to the next hemodialysis session (i.e., 68 hours post-infusion)|Time to Maximum Concentration, Sampling time at which maximum plasma concentration occurred, obtained directly from the experimental plasma concentration time data, without interpolation., Up to 68 hours post dose|Half-life, Apparent terminal half-life., Up to 68 hours post dose|Clearance of Daptomycin, Plasma clearance is dose (µg) divided by area under the concentration versus time curve from time 0 to last quantifiable concentration time., Up to 68 hours post dose|Volume of Distribution, Volume of distribution at steady state (mL) calculated as the product of clearance and mean residence time., Up to 68 hours post dose
|
| Locations: |
West Coast Clinical Trials, Cypress, California, 90630, United States|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States
|
